Published in final edited form as:

Biochem Pharmacol. 2004 March 1; 67(5): 893–901.

Structural determinants of efficacy at A₃ adenosine receptors: modification of the ribose moiety

Zhan-Guo Gao^a, Lak Shin Jeong^b, Hyung Ryong Moon^b, Hea Ok Kim^b, Won Jun Choi^b, Dae Hong Shin^b, Eleonora Elhalem^c, Maria J. Comin^c, Neli Melman^a, Liaman Mamedova^a, Ariel S. Gross^a, Juan B. Rodriguez^c, and Kenneth A. Jacobson^{a,*}

^aLaboratory of Bioorganic Chemistry, Molecular Recognition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

^bLaboratory of Medicinal Chemistry, College of Pharmacy, Ewha Womans University, Seoul 120-750, South Korea

^cDepartamento de Quimica Organica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellon 2, Piso 3, Ciudad Universitaria, Buenos Aires RA-1428, Argentina

Abstract

We have found previously that structural features of adenosine derivatives, particularly at the N⁶- and 2-positions of adenine, determine the intrinsic efficacy as A₃ adenosine receptor (AR) agonists. Here, we have probed this phenomenon with respect to the ribose moiety using a series of ribose-modified adenosine derivatives, examining binding affinity and activation of the human A₃ AR expressed in CHO cells. Both 2'- and 3'-hydroxyl groups in the ribose moiety contribute to A₃ AR binding and activation, with 2'-OH being more essential. Thus, the 2'-fluoro substitution eliminated both binding and activation, while a 3'-fluoro substitution led to only a partial reduction of potency and efficacy at the A₃ AR. A 5'-uronamide group, known to restore full efficacy in other derivatives, failed to fully overcome the diminished efficacy of 3'-fluoro derivatives. The 4'-thio substitution, which generally enhanced A₃ AR potency and selectivity, resulted in 5'-CH₂OH analogues (**10** and **12**) which were partial agonists of the A₃ AR. Interestingly, the shifting of the N⁶-(3-iodobenzyl)adenine moiety from the 1'- to 4'-position had a minor influence on A₃ AR selectivity, but transformed **15** into a potent antagonist (**16**) (*K_i* = 4.3 nM). Compound **16** antagonized human A₃ AR agonist-induced inhibition of cyclic AMP with a *K_B* value of 3.0 nM. A novel apio analogue (**20**) of neplanocin A, was a full A₃ AR agonist. The affinities of selected, novel analogues at rat ARs were examined, revealing species differences. In summary, critical structural determinants for human A₃ AR activation have been identified, which should prove useful for further understanding the mechanism of receptor activation and development of more potent and selective full agonists, partial agonists and antagonists for A₃ ARs.

Keywords

Nucleosides; A₃ adenosine receptor agonist; A₃ adenosine receptor antagonist; Adenylyl cyclase; Phospholipase C; Partial agonist

1. Introduction

Pharmacological characterization of the four subtypes of adenosine receptors (ARs; A₁, A_{2A}, A_{2B} and A₃) has been facilitated by the availability of potent and selective agonists and antagonists [1]. The A₁ and A₃ subtypes are negatively coupled to adenylyl cyclase, while A_{2A} and A_{2B} subtypes are positively coupled to this enzyme. A_{2B} and A₃ ARs are also positively coupled to phospholipase C [1]. The A₃ AR is the most recently identified AR subtype [2] and is involved in a variety of physiological processes [1]. The selective activation of A₃ ARs has been demonstrated to be both cardioprotective [3,4] and cerebroprotective [5,6]. Both selective agonists and antagonists [7] for A₃ ARs are of potential clinical use.

In an effort to develop potent agonists and antagonists for A₃ ARs, a wide range of N⁶- and 2'-substituted adenosine derivatives have recently been pharmacologically characterized [8–10]. We found that various adenosine derivatives, which were previously demonstrated to be agonists at A₁ and A_{2A} ARs and assumed to be full/partial agonists at A₃ ARs, are indeed antagonists at this subtype. Thus, the efficacy of adenosine derivatives appears to be more dependent on small structural changes at the A₃ AR than at other subtypes. Structural determinants critically involved in A₃ AR activation have been identified [8–13], leading to the conclusion that the ability of an adenosine derivative to activate the A₃ AR tends to be highly structure-sensitive. 3'-Fluoro has recently been found to interfere with A₃ AR binding [14], and certain 4'-thio nucleosides have been found to be potent and selective human A₃ AR agonists [15]. In this study, we further evaluated the binding affinity and functional properties of a series of ribose-modified adenosine derivatives, including some six previously reported compounds [14,15], at the human A₃ AR stably expressed in CHO cells.

2. Materials and methods

2.1. Cell culture and membrane preparation

Chinese Hamster Ovary (CHO) cells expressing recombinant human A₁ and A₃ ARs or HEK-293 cells expressing human A_{2A} ARs were cultured in DMEM and F12 (1:1) supplemented with 10% fetal bovine serum, 100 units mL⁻¹ penicillin, 100 µg mL⁻¹ streptomycin, 2 µmol mL⁻¹ glutamine and 800 µg mL⁻¹ geneticin. Cells were harvested and homogenized, and then centrifuged at 100 g for 5 min. The resulting pellet was re-suspended in 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl₂, 1 mM EDTA. The suspension was homogenized with an electric homogenizer for 10 s, and was then re-centrifuged at 20,000 g for 20 min at 4°. The resultant pellets were resuspended in buffer in the presence of 3 units mL⁻¹ adenosine deaminase, and the suspension was stored at -80° prior to the binding experiments. The membranes from rat forebrain and striatum were prepared as previously described [10]. Striatal and forebrain tissues from Wistar rats were homogenized in ice-cold 50 mM Tris-HCl buffer, pH 7.4, using an electric homogenizer. The homogenate was centrifuged at 20,000 g for 10 min at 4°, and the pellet was washed in fresh buffer. The final pellet was stored at -80° until the binding experiments. The protein concentration was measured using the Bradford assay [16].

2.2. Radioligand binding assay

For A₃ AR binding experiments, the procedures used were similar to those previously described [17]. Briefly, each tube contained 100 µL of membrane suspension (20 µg protein), 50 µL of [¹²⁵I]-AB-MECA (final concentration 1.0 nM), and 50 µL of increasing concentrations of compounds in Tris-HCl buffer (50 mM, pH 8.0) containing 10 mM MgCl₂, 1 mM EDTA. Nonspecific binding was determined using 10 µM Cl-IB-MECA. The mixtures were incubated at 25° for 60 min. Binding reactions were terminated by filtration

through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester (Brandell). Filters were washed three times with ice-cold buffer. Radioactivity was determined in a Beckman 5500B γ -counter. Binding assays were performed by methods previously described [10]. The binding to A₁ ARs utilized [³H]R-PIA (1.0 nM, rat forebrain) or [³H]CPX (0.5 nM, recombinant human A₁ AR), and the binding to A_{2A} ARs utilized [³H]CGS21680 (15 nM, rat striatum) and [³H]ZM241385 (2 nM, recombinant human A₁ AR).

2.3. Cyclic AMP accumulation assay

Intracellular cyclic AMP levels were measured with a competitive protein binding method [18]. CHO cell that expressed the recombinant human A₃ AR were harvested by trypsinization. After resuspension in medium, cells were planted in 24-well plates in 1 mL of medium. After 24 hr, the medium was removed and cells were washed with 1 mL DMEM, containing 50 mM HEPES, pH 7.4. Cells were then treated with agonists and/or test compounds (for study of the antagonistic effect, antagonists were preincubated in the medium for 30 min before the addition of agonist) in the presence of rolipram (10 μ M) and adenosine deaminase (3 units mL⁻¹). After 45 min forskolin (10 μ M) was added to the medium, and the incubation was continued an additional 15 min. The reaction was terminated by removal of the supernatant, and cells were lysed upon addition of 200 μ L of ice-cold 0.1 M HCl. The cell lysate was resuspended and stored at -20°. For determination of cyclic AMP production, protein kinase A (PKA) was incubated with [³H]cyclic AMP (2.0 nM) in K₂HPO₄/EDTA buffer (K₂HPO₄, 150 mM; EDTA, 10 mM), 20 μ L of the cell lysate, and 30 μ L 0.1 M HCl or 50 μ L of cyclic AMP solution (0–16 pmol/200 μ L for standard curve). Bound radioactivity was separated by rapid filtration through Whatman GF/C filters and washed once with cold buffer. Bound radioactivity was measured using a liquid scintillation counter (LKB Wallace 1215 Rackbeta scintillation counter).

2.4. Inositol phosphate determination

The method used was similar to that previously described [13]. Briefly, cells were harvested by trypsinization and grown in six-well plates (~10⁶ cells per well; Costar) in DMEM culture medium supplemented with 2 μ Ci mL⁻¹ of *myo*-[³H]inositol. The mixtures were swirled to ensure uniformity. After a labeling period of 24 hr, cells were preincubated in the presence of 3 units mL⁻¹ adenosine deaminase for 30 min at 37° with 10 mM LiCl and for 20 min at room temperature. Following the addition of the test compounds, the cells were incubated for 30 min at 37°. The supernatants were removed by aspiration, and 500 μ L of cold 20 mM formic acid was added to each well. Cell extracts were collected after a 30-min incubation at 4° and neutralized with 300 μ L of 60 mM NH₄OH. The inositol monophosphate fraction was then isolated by anion exchange chromatography. The content of each well was applied to a small anion exchange column (AG-1-X8; BioRad) that had been pretreated with 15 mL of 0.1 M formic acid/3 M ammonium formate, followed by 15 mL of water. The columns were then washed with 15 mL of a solution containing 5 mM sodium borate and 60 mM sodium formate. [³H]Inositol phosphates (IP) were eluted two times with 5 mL of 0.1 M formic acid/0.2 M ammonium formate and radioactivity was quantified by liquid scintillation counting (LKB Wallace 1215 Rackbeta scintillation counter).

2.5. Materials

[³H]R-PIA (34 Ci mmol⁻¹), [¹²⁵I]N⁶-(4-amino-3-iodobenzyl)adenosine-5'-*N*-methyluronamide ([¹²⁵I]I-AB-MECA; 2000 Ci mmol⁻¹), and [³H]cyclic AMP (40 Ci mmol⁻¹) were from Amersham Pharmacia Biotech. [³H]CGS21680 (47 Ci mmol⁻¹) was from Perkin-Elmer Life Sciences. CI-IB-MECA, CPA, CCPA and NECA were purchased

from Sigma-RBI. MRS 542, MRS 1743, and MRS 1760 were prepared as described [9]. All other reagents were from standard commercial sources and of analytical grade.

2.6. Statistical analysis

Binding and functional parameters were estimated using GraphPAD Prism software. IC₅₀ values obtained from competition curves were converted to K_i values as described [19]. Data were expressed as mean $\pm$ standard error.

3. Results

3.1. Structures of ribose-modified nucleoside analogues

A series of ribose-modified analogues of adenosine agonists (Fig. 1) was synthesized [14,15,20,21] and compared in binding and functional assays (Table 1). The set of analogues included nucleosides having a 5'-uronamide modification (**1**, **2**, **8**, **9**, and **13–16**), modification of a hydroxy group either through chiral inversion (**3**) or through fluoro-substitution (**4–9**), or a 4'-thio modification (**10–15**). 3'-Fluoro (**7–9**) and 5'-uronamide-4'-thionucleoside (**13–15**) analogues were reported previously and partially characterized pharmacologically [15]. Other species included were nucleoside-like analogues, i.e. a rearranged 4'-thionucleoside analogue (**16**) and those having carbocyclic rings (**17–22**). Substitution of the adenine moiety, where present, followed previously determined substitution patterns to obtain high affinity at the human A₃ AR, such as *N*⁶-methyl and *N*⁶-iodobenzyl groups, either alone or in combination with the 2-chloro substituent. Use of the *N*⁶-methyl substituent for A₃ AR agonism by Cristalli and coworkers was usually accompanied by additional substitution at the 2-position [22]. The synthesis of the novel analogues in the present study (**3–6**, **10–12**, **16–19**, **21**) will be described in detail elsewhere,¹ however high purity and identity were ascertained through spectral means.

3.2. Binding affinity of ribose-modified nucleoside analogues

In binding (Table 1), high affinity for the human A₃ AR ($K_i < 10$ nM) was found for compounds **1** and **2** (the reference agonists IB-MECA and CI-IB-MECA) and for 4'-thionucleosides **10–12** and **16**, extending previous observations obtained for the 5'-uronamides **13–15** [15]. Compound **16** is a novel structure having a drastic alteration in the connectivity of the structure, i.e. the adenine moiety has been shifted from the 1'- to 4'-position, but with the striking finding that the AR binding profiles and selectivity are similar in both cases. Several compounds were of intermediate affinity (K_i of 10 nM–1 μ M) at the human A₃ AR, in the order of decreasing affinity: the novel 4'-fluoro-(*N*)-methanocarba derivative **21** > the 3'-fluoro derivatives **7**, **8** > **6**, **9**. Fluoro analogues **4** and **5**, with fluorine at the ribose 2'-position, and **17**, the 4'-fluoro analogue of neplanocin A, did not bind appreciably to the human A₃ AR. For comparison with affinities at other subtypes, the compounds were examined in binding experiments at the human A₁ and A_{2A} ARs. A high degree of selectivity (>100-fold) for the human A₃ AR vs. the human A₁ and A_{2A} ARs was found for 4'-thionucleosides **10–15**.

3.3. Functional potency and efficacy of ribose-modified nucleoside analogues

The activation of the human A₃ AR by this series of ribose-modified adenosine derivatives (Table 1) was examined by measuring their effects on forskolin-stimulated cyclic AMP accumulation in CHO cells stably expressing the human A₃ AR. As shown in Fig. 2, the potent and selective A₃ AR agonist IB-MECA maximally inhibited the forskolin-stimulated cyclic AMP production by approximately 50%, and this level of inhibition of adenylate

¹Jeong and coworkers, unpublished.

cyclase was taken as the 100% reference point in Table 1. CI-IB-MECA was demonstrated to be equiefficacious as IB-MECA.

The 4'-thionucleosides **11** and **13–15**, and compound **20** were found to be full agonists at the human A₃ AR. Compound **20** is a novel apio analogue of neplanocin A [21] in which the 4'-CH₂OH group has been displaced to the 3'-position. Nevertheless, this highly modified carbocyclic nucleoside analogue fully activated the human A₃ AR.

Partial agonists were also identified among the novel analogues. For example, the 4'-thionucleoside **10**, which is similar to the reference agonist 2-chloroadenosine (CADO), was shown to be less efficacious than the full agonist CADO [9]. The 4'-thionucleoside **12**, which is similar to the reference nucleoside MRS 542 [9], was shown to be more efficacious than its oxygen analogue. A 3'-fluoro group was less detrimental for recognition by the human A₃ AR than a 2'-fluoro group [14], however the reduction of efficacy by the 3'-fluoro group was substantial. Thus, compounds **7** and **9** were antagonists, while compounds **6** and **8** were partial agonists at the human A₃ AR. Other partial agonists found were: a 4'-chloro neplanocin A derivative **18** and the 4'-fluoro-(*N*)-methanocarpa derivative (**21**). The 4'-iodoneplanocin A derivative (**19**) was weaker in binding to the A₃ AR than its 4'-chloro analogue, however there was an indication of partial agonism for that derivative as well.

Strikingly, it was evident that structural changes in the ribose moiety, in addition to the 3'-fluoro substitution, were able to completely eliminate activation of the human A₃ AR without elimination of binding affinity. Thus, compounds **16** and **22** were antagonists at this receptor. At the human A₁ AR, compound **16** displayed a *K_i* value of 110 ± 12 nM, while at the human A_{2A} AR, the displacement reached only less than 50% at 10 μM. Thus, a significant degree of A₃ AR binding selectivity (26-fold vs. A₁ AR, >100-fold vs. A_{2A} AR) was seen among the human subtypes. Compound **22**, neplanocin C [20], although weaker in binding to the A₃ AR than the antagonist **16**, was noteworthy in that it was otherwise unsubstituted on the adenine moiety.

The structurally unique compound **16** was examined in another functional assay. The activation of phospholipase C (PLC) was studied in CHO cells expressing the human A₃ AR (Fig. 3A). While CI-IB-MECA displayed an EC₅₀ of 16.6 ± 2.6 nM (N = 4), compound **16** (0.01–10 μM) failed to stimulate, suggesting that it may be an antagonist. This was confirmed (Fig. 3B) in an experiment in which compound **16** effectively antagonized the effects of CI-IB-MECA to activate PLC. Furthermore, compound **16** antagonized the effects of CI-IB-MECA on forskolin-stimulated cyclic AMP production (Fig. 4). Schild analysis [23] indicated a *K_B* value of 3.0 nM for inhibition of this functional effect of the human A₃ AR. In contrast to compound **16**, the 4'-thionucleoside (**15**) was a potent full agonist (Table 1).

3.4. Activity of selected ribose-modified nucleoside analogues at other ARs

Compound **16** has moderate affinity for the human A₁ AR, however, it was not known whether it was an agonist or antagonist at this subtype. Hence, we further examined its effect on forskolin-stimulated cyclic AMP production in CHO cells expressing human A₁ ARs. As shown in Fig. 5, both CPA and CCPA are potent agonists for human A₁ ARs, while no significant activation by compound **16** was demonstrated. In comparison, MRS 1743 and MRS 1760, which are potent, yet low efficacy partial agonist/antagonists at the human A₃ AR [9], were shown to fully activate the human A₁ AR.

3.5. Species differences: comparison with rat ARs

As demonstrated earlier, pronounced species differences of some adenosine derivatives have been found among human and rat A₃ ARs [10]. Selected compounds were tested in binding

to three subtypes of rat ARs (Table 2). Here we show that species differences were also pronounced for some compounds of this series, especially at A₃ ARs (Fig. 6). Compounds **7**, **13**, **14**, **16**, and **21** showed much higher affinity for human than for rat A₃ ARs (12-, 13-, 85-, 22-, and 22-fold, respectively). The A₁ and A_{2A} AR affinities of **13** were also diminished in rat compared to human. Compound **15** showed a similar affinity for human and rat A₃ ARs (approximately 2-fold difference), and thus retained A₃ AR selectivity in the rat.

4. Discussion

In previous studies it has been demonstrated that the intrinsic efficacy of adenosine derivatives in human A₃ AR activation depended upon both N⁶- and 2-substitutions at the adenine moiety [8–12]. For example, N⁶-substituents consisting of a large cycloalkyl group (>5 carbons) reduced efficacy compared to smaller rings in the activation of the human A₃ AR. Here, we further demonstrated that the simultaneous exocyclic and cyclic substitution of the ribose moiety also contributed differentially to the affinity and efficacy at the human A₃ AR.

Our earlier studies [8–10] demonstrated that some full A₁ AR agonists, including 2-chloro analogues, have reduced intrinsic efficacy at the human A₃ AR. For example, 2-chloro-*R*-PIA was a partial A₃ AR agonist, and CCPA was an antagonist. The N⁶-derivative DPMA, a potent A_{2A} AR agonist [24], was also demonstrated to be a moderately potent antagonist at the A₃ AR [10]. In the present study, the newly synthesized adenosine derivative **16** was demonstrated to be a potent antagonist for human A₃ AR. In contrast to CCPA and DPMA, **16** is an antagonist for both human A₁ and human A₃ ARs. It is not yet known whether **16** is an agonist or antagonist at the A_{2A} AR, due to its extremely low affinity at this receptor.

The stereochemistry and substitution of the ribose hydroxyl groups greatly affected the intrinsic efficacy. The arabino derivative (**3**) displayed greatly reduced A₃ AR binding affinity due to inversion of stereochemistry at the 3'-carbon. Like its stereoisomer MRS 542 [9], it did not display agonist action at the human A₃ AR. In compounds **4** and **5**, a 2'-fluoro group greatly attenuated human A₃ AR binding. The 3'-fluoro substitution, as in **6**, allowed a greater degree of agonism than when fluoro was present at the 2'-position. The human A₃ AR affinity of the 3'-fluoro analogue **7** was 42-fold weaker than the affinity of the corresponding riboside MRS 542, and, like MRS 542, it was an antagonist at this subtype. The loss of intrinsic efficacy of 3'-fluoro analogues (**6**, **7**) could be partly overcome by the presence of a 5'-uronamide group for an N⁶-methyl analogue (**8**), but not for a N⁶-(3-iodobenzyl) analogue (**9**). Previously, it was found that the agonism of other low efficacy A₃ AR agonists was fully restored by a 5'-uronamide group [9], unlike the present case.

The 4'-thio modification [15] generally enhanced potency (as in **10**), yet decreased efficacy. Thus, 4'-thio substituted 5'-CH₂OH analogues **10** and **12** were partial agonists of the A₃ AR. The N⁶-methyl group in **11** counter-acted the potency-reducing effect of a 2-Cl group; thus **11** was a very potent agonist. The 4'-thio group of **12** increased efficacy in comparison to its oxygen analogue MRS 542. Compounds **13–15** were potent, full agonists, consistent with the ability of a flexible 5'-amide group to overcome various efficacy-reducing structural changes [9]. The rearranged analogue **16** was a potent, selective antagonist. The SAR comparison of **10–12** vs. compounds **13–15** suggests that an analogue of **16** where the *N*-methylcarboxamide is replaced by a hydroxymethyl group would be an interesting compound. Carbocyclic derivatives were found to be of variable affinity and intrinsic efficacy. Although compound **17** was inactive as either agonist or antagonist, compound **18** was a weak agonist. Compound **20** was the first example of this structural class shown to interact with adenosine receptors.

The present study together with our earlier studies [10] suggested that the *N*⁶-methyl group is extremely favorable for human A₃ AR affinity and selectivity. Thus, both **11** and **14** are potent and selective agonists for the A₃ AR. This finding extended our previous observation that *N*⁶-iodobenzyl group is optimal for A₃ AR affinity and selectivity [25]. However, it should be noted that the *N*⁶-methyl group is somewhat detrimental to the binding affinity at the rat A₃ AR.

Recent findings indicated that some compounds might activate two different subtypes of a certain receptor family, both leading to beneficial effects. Some other compounds might activate a specific receptor subtype that is beneficial, while blocking another subtype that might lead to the harmful effects associated with adenosine. The dual-acting ligands of ARs may have considerable promise as novel approaches to treat ischemic conditions. It has been suggested that activation of both A₁ and A₃ ARs may have cardioprotective effects but via different mechanisms [26,27]. Hence, dual acting agonists for A₁ and A₃ ARs might be useful for cardioprotection. In contrast to the effect of AR activation on the heart, pretreatment with an A₁ agonist or an A₃ antagonist protects the kidney from a subsequent prolonged ischemic insult [28]. The role of the A₃ AR in kidney function was further confirmed by the fact that A₃ AR knockout mice are protected against ischemia-and myoglobinuria-induced renal failure [29]. Hence, dual-acting compounds (activating A₁ and blocking A₃ ARs), such as CCPA, might be useful for protection of ischemic condition of kidney. It may be speculated that agonists blocking both A₁ and A₃ ARs while activating A_{2A} ARs may also have potential clinical use. Compound **16** could serve as a starting point for this series. Novel and unique ligands may be identified by optimizing the selectivity, efficacy and binding affinity of the adenosine derivatives at different AR subtypes.

In conclusion, critical structural determinants for A₃ AR activation have been identified by modifying the ribose moiety of adenosine or adenosine derivatives, which should prove useful for further understanding of the mechanism of receptor activation and development of more potent and selective full agonists, partial agonists and antagonists for A₃ ARs.

Acknowledgments

We thank Prof. Gary Stiles (Duke University) for the gift of CHO cells expressing the human and rat A₃ receptors. We thank Prof. Joel Linden (University of Virginia) for the gift of HEK-293 cells expressing the human A_{2A} receptor.

Abbreviations

CI-IB-MECA	2-chloro- <i>N</i> ⁶ -(3-iodobenzyl)-5'- <i>N</i> -methyl-carbamoyl adenosine
CGS21680	2-[<i>p</i> -(2-carboxyethyl)phenylethylamino]-5'- <i>N</i> -ethylcarboxamidoadenosine
CCPA	2-chloro- <i>N</i> ⁶ -cyclopentyladenosine
DPMA	<i>N</i> ⁶ -[2-(3,5-dimethoxyphenyl)-2-(2-methylphenylethyl)]adenosine
CADO	2-chloroadenosine
DMSO	dimethylsulfoxide
GPCR	G protein-coupled receptor
Tris	tris(hydroxymethyl)aminomethane
I-AB-MECA	<i>N</i> ⁶ -(4-amino-3-iodobenzyl)-5'- <i>N</i> -methylcarboxamidoadenosine
MRS 542	2-chloro- <i>N</i> ⁶ -(3-iodobenzyl)adenosine

MRS 1743	<i>N</i> ⁶ -(3-iodobenzyl)-(N)-methanocarbaadenosine
MRS 1760	2-chloro- <i>N</i> ⁶ -(3-iodobenzyl)-(N)-methanocarbaadenosine
NECA	5'- <i>N</i> -ethylcarboxamidoadenosine
R-PIA	<i>R</i> - <i>N</i> ⁶ -[2-phenylisopropyl]adenosine

References

1. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev.* 2001; 53:527–52. [PubMed: 11734617]
2. Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, Civelli O. Molecular cloning and characterization of an adenosine receptor: the A₃ adenosine receptor. *Proc Natl Acad Sci USA.* 1992; 89:7432–6. [PubMed: 1323836]
3. Liang BT, Jacobson KA. A physiological role of the adenosine A₃ receptor: sustained cardioprotection. *Proc Natl Acad Sci USA.* 1998; 95:6995–9. [PubMed: 9618527]
4. Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ. A₃ adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. *Am J Physiol Heart Circ Physiol.* 2003; 285:H607–13. [PubMed: 12689858]
5. Von Lubitz DK, Lin RC, Popik P, Carter MF, Jacobson KA. Adenosine A₃ receptor stimulation and cerebral ischemia. *Eur J Pharmacol.* 1994; 263:59–67. [PubMed: 7821362]
6. Fedorova IM, Jacobson MA, Basile A, Jacobson KA. Behavioral characterization of mice lacking the A₃ adenosine receptor: sensitivity to hypoxic neurodegeneration. *Cell Mol Neurobiol.* 2003; 23:431–47. [PubMed: 12825837]
7. Avila MY, Stone RA, Civan MM. Knockout of A₃ adenosine receptors reduces mouse intraocular pressure. *Invest Ophthalmol Vis Sci.* 2002; 43:3021–6. [PubMed: 12202525]
8. Gao ZG, Jacobson KA. 2-Chloro-*N*⁶-cyclopentyladenosine, adenosine A₁ receptor agonist, antagonizes the adenosine A₃ receptor. *Eur J Pharmacol.* 2002; 443:39–42. [PubMed: 12044789]
9. Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA. Structural determinants of A₃ adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. *J Med Chem.* 2002; 45:4471–84. [PubMed: 12238926]
10. Gao ZG, Blaustein JB, Gross AS, Melman N, Jacobson KA. *N*⁶-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A₃ adenosine receptor. *Biochem Pharmacol.* 2003; 65:1675–84. [PubMed: 12754103]
11. Van Tilburg EW, Von Frijtag Drabbe Künzel J, De Groote M, Vollinga RC, Lorenzen A, Ijzerman AP. *N*⁶,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A₃ receptor. *J Med Chem.* 1999; 42:1393–400. [PubMed: 10212125]
12. Van Tilburg EW, Van Der Klein PA, Von Frijtag Drabbe Kunzel J, De Groote M, Stannek C, Lorenzen A, Ijzerman AP. 5'-*O*-alkyl ethers of *N*⁶,2-substituted adenosine derivatives: partial agonists for the adenosine A₁ and A₃ receptors. *J Med Chem.* 2001; 44:2966–75. [PubMed: 11520205]
13. Gao ZG, Chen A, Barak D, Kim SK, Müller CE, Jacobson KA. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A₃ adenosine receptor. *J Biol Chem.* 2002; 277:19056–63. [PubMed: 11891221]
14. Lim MH, Kim HO, Moon HR, Lee SJ, Chun MW, Gao ZG, Melman N, Jacobson KA, Kim JH, Jeong LS. Design, synthesis and binding affinity of 3'-fluoro analogues of Cl-IB-MECA as adenosine A₃ receptor ligands. *Bioorg Med Chem Lett.* 2003; 13:817–20. [PubMed: 12617898]
15. Jeong LS, Jin DZ, Moon HR, Kim HO, Chun MW, Melman N, Gao ZG, Jacobson KA. *N*⁶-Substituted D-4'-thioadenosine-5'-uronamides: potent and selective agonists at the human A₃ adenosine receptor. *J Med Chem.* 2003; 46:3775–7. [PubMed: 12930138]
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 1976; 72:248–54. [PubMed: 942051]

17. Olah ME, Gallo-Rodriguez C, Jacobson KA, Stiles GL. ^{125}I -4-Amino-benzyl-5'-*N*-methylcarboxamido-adenosine, a high affinity radioligand for the rat A_3 adenosine receptor. *Mol Pharmacol*. 1994; 45:978–82. [PubMed: 8190112]
18. Nordstedt C, Fredholm BB. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. *Anal Biochem*. 1990; 189:231–4. [PubMed: 2177960]
19. Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (I_{50}) of an enzymatic reaction. *Biochem Pharmacol*. 1973; 22:3099–108. [PubMed: 4202581]
20. Comin MJ, Rodriguez JB. First synthesis of (–)-neplanocin C. *Tetrahedron*. 2000; 56:4639–49.
21. Moon HR, Kim HO, Lee KM, Chun MW, Kim JH, Jeong LS. Stereoselective synthesis of a novel apio analogue of neplanocin A as potential *S*-adenosylhomocysteine hydrolase inhibitor. *Org Lett*. 2002; 4:3501–3. [PubMed: 12323054]
22. Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G. N^6 -Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A_3 receptor and a starting point for searching $\text{A}_{2\text{B}}$ ligands. *J Med Chem*. 2002; 45:3271–9. [PubMed: 12109910]
23. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. *Br J Pharmacol Chemother*. 1959; 14:48–58. [PubMed: 13651579]
24. Bridges AJ, Bruns RF, Ortwine DF, Priebe SR, Szotek DL, Trivedi BK. N^6 -[2-(3,5-Dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A_2 receptor. *J Med Chem*. 1988; 31:1282–5. [PubMed: 3385722]
25. Gallo-Rodriguez C, Ji XD, Melman N, Siegman BD, Sanders LH, Orlina J, Fischer B, Pu Q, Olah ME, Van Galen PJ, Stiles GL, Jacobson KA. Structure–activity relationships of N^6 -benzyladenosine-5'-uronamides as A_3 -selective adenosine agonists. *J Med Chem*. 1994; 37:636–46. [PubMed: 8126704]
26. Parsons M, Young L, Lee JE, Jacobson KA, Liang BT. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. *FASEB J*. 2000; 14:1423–31. [PubMed: 10877835]
27. Takano H, Bolli R, Black RG Jr, Kodani E, Tang XL, Yang Z, Bhattacharya S, Auchampach JA. A_1 or A_3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. *Circ Res*. 2001; 88:520–8. [PubMed: 11249876]
28. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A_1 and A_3 receptors. *Am J Physiol Renal Physiol*. 2000; 278:380–7.
29. Lee HT, Ota-Setlik A, Xu H, D'Agati VD, Jacobson MA, Emala CW. A_3 adenosine receptor knockout mice are protected against ischemia-and myoglobinuria-induced renal failure. *Am J Physiol Renal Physiol*. 2003; 284:267–73.

Fig. 1.
Structures of the ribose-modified adenosine derivatives studied as agonists, partial agonists, and antagonists of the human A₃ AR.

Fig. 2.

Inhibition of forskolin-stimulated cyclic AMP production in CHO cells stably transfected with the human A₃ AR, induced by various adenosine derivatives. All experiments were performed in the presence of 10 μ M rolipram and 3 units mL⁻¹ adenosine deaminase. Forskolin (10 μ M) was used to stimulate cyclic AMP levels. The level of cAMP corresponding to 100% was 220 ± 30 pmol mL⁻¹. The data shown were from one experiment performed in duplicate and are typical of three independent experiments giving similar results. EC₅₀ values from three independent experiments were listed in Table 1.

Fig. 3.

(A) Stimulation of phospholipase C activity in CHO cells stably transfected with the human A₃ AR by CI-IB-MECA **2** ($EC_{50} = 16.6 \pm 2.6$ nM, $N = 4$) and lack of stimulation by **16**. (B) Antagonism of the effects of CI-IB-MECA (100 nM) by **16** at two concentrations. The procedures were described in Section 2. The data shown are from one representative experiment performed in duplicate. The EC_{50} value was from four independent experiments performed in duplicate.

Fig. 4.

Antagonism by **16** of the inhibition of cyclic AMP production elicited by Cl-IB-MECA in CHO cells stably transfected with the human A₃ AR. All experiments were performed in the presence of 10 μ M rolipram and 3 units mL⁻¹ adenosine deaminase. Forskolin (10 μ M) was used to stimulate cyclic AMP levels. The level of cAMP corresponding to 100% was 220 ± 30 pmol mL⁻¹. The data shown were from one experiment performed in duplicate and are typical of three independent experiments giving similar results. The K_B value for **16** was calculated to be 3.0 nM.

Fig. 5.

Inhibition of forskolin-stimulated cyclic AMP production in CHO cells stably transfected with the human A₁ AR, induced by various adenosine derivatives. All experiments were performed in the presence of 10 μ M rolipram and 3 units mL⁻¹ adenosine deaminase. Forskolin (10 μ M) was used to stimulate cyclic AMP levels. The level of cAMP corresponding to 100% was 247 ± 52 pmol mL⁻¹. The data shown were from one experiment performed in duplicate and are typical of three independent experiments giving similar results. EC₅₀ values were (nM): CPA, 2.2 ± 0.5 ; CCPA, 2.8 ± 0.8 ; MRS 1743, 78 ± 23 ; MRS 1760, 97 ± 36 .

Fig. 6.

Species differences in affinity as illustrated by competition for radioligand binding ($[^{125}\text{I}]\text{-AB-MECA}$) at rat and human A_3 ARs, by six representative adenosine analogues **7**, **13–16** and **21**. All except **15** were significantly more potent at human than at rat A_3 ARs. The procedures were described in Section 2. The data points are from a representative experiment performed in duplicate. The mean K_i values for rat A_3 ARs calculated from three independent experiments are provided in Table 2.

Binding affinity at human A₁, A_{2A} and A₃ ARs, and functional potency and efficacy (inhibition of forskolin-stimulated cyclic AMP accumulation at 10 μ M) at human A₃ ARs^a

Table 1

Compound	K _i (nM) or percentage inhibition at 10 mM			EC ₅₀ (nM) hA ₃	Efficacy hA ₃
	hA ₁	hA _{2A}	hA ₃		
1 IB-MECA	1620 $\pm$ 760	2910 $\pm$ 580	1.8 $\pm$ 0.7 ^b	3.6 $\pm$ 1.3 ^b	100% ^b
2 Cl-IB-MECA	1240 $\pm$ 320 ^{c,d}	5360 $\pm$ 2470 ^{c,d}	1.4 $\pm$ 0.3 ^b	2.8 $\pm$ 1.4 ^b	99 $\pm$ 6% ^b
3	23%	0%	3940 $\pm$ 1320	NA	0%
4	0%	0%	7%	NA	0%
5	0%	0%	44%	NA	6 $\pm$ 4%
6^d	20% ^{c,e}	0% ^{c,e}	326 $\pm$ 112 ^e	1380 $\pm$ 350	17 $\pm$ 8%
7^d	4640 $\pm$ 340 ^{c,e}	0%	75 $\pm$ 7	NA	0%
8	10%	7% ^{c,e}	127 $\pm$ 44 ^e	1170 $\pm$ 350	54 $\pm$ 7%
9^d	6% ^{c,e}	0% ^{c,e}	406 $\pm$ 60 ^e	NA	0%
10	47%	2440 $\pm$ 316	4.9 $\pm$ 1.3	17.3 $\pm$ 3.4	64 $\pm$ 18%
11	629 $\pm$ 168	4%	0.8 $\pm$ 0.1	2.3 $\pm$ 0.8	96 $\pm$ 5%
12	554 $\pm$ 64	1190 $\pm$ 293	3.2 $\pm$ 0.9	3.0 $\pm$ 1.1	32 $\pm$ 7%
13	89.2 $\pm$ 11.7 ^{c,d}	158 $\pm$ 29 ^{c,d}	0.40 $\pm$ 0.06 ^d	1.0 $\pm$ 0.3	100 $\pm$ 5%
14	1330 $\pm$ 242 ^{c,d}	20% ^{c,d}	0.28 $\pm$ 0.09 ^d	0.21 $\pm$ 0.04	119 $\pm$ 12%
15	193 $\pm$ 46 ^{c,d}	223 $\pm$ 36 ^{c,d}	0.38 $\pm$ 0.07 ^d	0.38 $\pm$ 0.06	114 $\pm$ 9%
16	110 $\pm$ 12	47%	4.3 $\pm$ 1.2	NA	0%
17	7%	9%	49%	NA	28 $\pm$ 7%
18	7%	6%	3150 $\pm$ 680	1150 $\pm$ 380	42 $\pm$ 18%
19	5%	3%	6490 $\pm$ 1780	NA	8 $\pm$ 3%
20	8%	0%	628 $\pm$ 69	717 $\pm$ 221	101 $\pm$ 4%
21	1590 $\pm$ 121	5530 $\pm$ 693	26 $\pm$ 12	18.2 $\pm$ 7.1	33 $\pm$ 10%
22	1%	0%	1130 $\pm$ 350	NA	0%

Values are means $\pm$ SEM. NA, not applicable.

^aAll A₃ AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding the human A₃ AR using [¹²⁵I]-AB-MECA as radioligand. Binding at A₁ and A_{2A} ARs was carried out as described in Section 2 using [³H]CPX or [³H]ZM241385 as radioligand, unless noted. Values from the present study are means ± SEM, N = 3.

^bData from Gao *et al.* [10].

^cBinding using [³H] PIA (A₁ AR) or [³H]CGS21680 (A_{2A} AR).

^dData from Jeong *et al.* [15].

^eData from Lim *et al.* [14].

Table 2Binding affinities of selected compounds at rat A₁, A_{2A} and A₃ ARs (K_i , nM)^a

Compound	rA ₁	rA _{2A}	rA ₃
7	1350 ± 350 ^b	>10,000 ^b	910 ± 240
13	294 ± 115 ^c	442 ± 148	13.4 ± 4.3
14	198 ± 14 ^c	6,340 ± 90 ^c	23.8 ± 11.2
15	140 ± 43 ^c	348 ± 110 ^c	0.82 ± 0.27
16	188 ± 40	>10,000	95 ± 12
21	417 ± 119	>10,000	570 ± 240

^a All A₃ AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding the rat A₃ AR using [¹²⁵I]-AB-MECA as radioligand. Binding at rat forebrain A₁AR and rat striatal A_{2A} AR in this study was carried out as described in Section 2 using [³H]PIA or [³H]CGS21680 as radioligand. Values from the present study are means ± SEM, N = 3.

^b Data from Lim *et al.* [14].

^c Data from Jeong *et al.* [15].